

Financial news for OCUL dated on 2020-06-08: Shares of several healthcare companies are trading higher on continued optimism amid the reopening of the economy, which would increase consumer spending and economic activity.

Financial news for OCUL dated on 2020-05-26: 71 Biggest Movers From Friday

Financial news for OCUL dated on 2020-05-20: Ocular Therapeutix shares are trading lower after the company priced its 8.18 million share offering of its common stock at \$5.50 per share. UPDATE: Shares have since reversed, now higher.

Financial news for OCUL dated on 2020-05-20: The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test

Financial news for OCUL dated on 2020-05-20: Ocular Therapeutix Says Public Offering Of 8.18M Common Shares Priced At \$5.50/Share

Financial news for OCUL dated on 2020-05-19: Ocular Therapeutix Announces Proposed Public Offering of Common Stock; Size Not Disclosed

Financial news for OCUL dated on 2020-05-18: 70 Biggest Movers From Friday

Financial news for OCUL dated on 2020-05-13: Shares of several companies in the broader healthcare sector are trading lower amid market weakness despite recent strength from many names in the space. Equities are down for the session following cautious comments from US Fed Chair Powell, which forecast uncertainty and downside risk. Some regions of the US have extended lockdown restrictions, including Washington D.C. and Los Angeles County.

Financial news for OCUL dated on 2020-05-12: Ocular Therapeutix Announces First Patient Dosed In Phase 1 Clinical Trial Of OTX-CSI For The Treatment Of Dry Eye Disease

Financial news for OCUL dated on 2020-05-08: Ocular Therapeutix: Q1 Earnings Insights

Financial news for OCUL dated on 2020-05-08: The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda

Financial news for OCUL dated on 2020-05-08: Ocular Therapeutix Q1 GAAP EPS \$(0.410) May Not Compare \$(0.370) Estimate, Sales \$2.600M Miss \$2.840M Estimate

Financial news for OCUL dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for OCUL dated on 2020-04-29: Ocular Therapeutix shares are trading higher after HC Wainwright maintained its Buy rating on the stock and raised its price target from \$8 to \$10 per share.

Financial news for OCUL dated on 2020-04-29: HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Raises Price Target to \$10

Financial news for OCUL dated on 2020-04-28: 34 Stocks Moving in Tuesday's Pre-Market Session

Financial news for OCUL dated on 2020-04-28: UPDATE: Ocular Therapeutix Says Intends To Submit Supplemental New Drug Application To Expand DEXTENZA's Label To Include Treatment Of Ocular Itching Associated With Allergic Conjunctivitis In 2020

Financial news for OCUL dated on 2020-04-28: Ocular Therapeutix Reports Data From Phase 3 Trial Showed Statistically Significance Effect Achieved At All Pre-Specified Primary Endpoints

Financial news for OCUL dated on 2020-03-17: Jefferies Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces \$8 Price Target

Financial news for OCUL dated on 2020-03-13: The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings

Financial news for OCUL dated on 2020-03-12: The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

Financial news for OCUL dated on 2020-03-12: Earnings Scheduled For March 12, 2020

Financial news for OCUL dated on 2020-03-08: The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues

Financial news for OCUL dated on 2020-03-06: The Daily Biotech Pulse: Breakthrough Device Designation For Neuronetics, AbbVie Receives European Label Expansion,

AstraZeneca Flunks Late-Stage Study

Financial news for OCUL dated on 2020-03-05: Stocks That Hit 52-Week Highs On Thursday

Financial news for OCUL dated on 2020-03-05: Piper Sandler Reiterates Overweight on Ocular Therapeutix, Raises Price Target to \$11

Financial news for OCUL dated on 2020-03-05: The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19

Financial news for OCUL dated on 2020-03-05: 92 Biggest Movers From Yesterday

Financial news for OCUL dated on 2020-03-04: Mid-Afternoon Market Update: Dow Jumps Over 800 Points; Cardlytics Shares Slide

Financial news for OCUL dated on 2020-03-04: 60 Stocks Moving In Wednesday's Mid-Day Session

Financial news for OCUL dated on 2020-03-04: Mid-Day Market Update: Owens & Minor Falls On Weak Sales; Collect Biotechnology Shares Climb

Financial news for OCUL dated on 2020-03-04: Stocks That Hit 52-Week Highs On Wednesday

Financial news for OCUL dated on 2020-03-04: Shares of several healthcare-related companies are trading higher after Joe Biden secured several key wins in Super Tuesday. Biden's more 'moderate' healthcare policies have been seen as more favorable for the sector.

Financial news for OCUL dated on 2020-03-04: 85 Biggest Movers From Yesterday

Financial news for OCUL dated on 2020-03-03: Raymond James Upgrades Ocular Therapeutix to Strong Buy, Raises Price Target to \$15

Financial news for OCUL dated on 2020-03-03: Ocular Therapeutix Reports Prelim. Q4 Sales \$2.3M

Financial news for OCUL dated on 2020-02-21: Stocks That Hit 52-Week Highs On Friday

Financial news for OCUL dated on 2020-02-13: The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO

Financial news for OCUL dated on 2020-02-10: H.C. Wainwright Reiterates Buy on Ocular Therapeutix, Raises Price Target to \$8

Financial news for OCUL dated on 2020-02-07: Ocular Therapeutix Highlights Presentation Of Data Showing Clinically-Meaningful Reduction In Intraocular Pressure In Patients With Primary Open Angle Glaucoma or Ocular Hypertension Treated with OTX-TIC at Glaucoma 360 Conference

Financial news for OCUL dated on 2020-01-22: 82 Biggest Movers From Yesterday

Financial news for OCUL dated on 2020-01-21: 55 Stocks Moving In Tuesday's Mid-Day Session

Financial news for OCUL dated on 2020-01-06: 53 Biggest Movers From Friday

Financial news for OCUL dated on 2020-01-03: 30 Stocks Moving In Friday's Mid-Day Session

Financial news for OCUL dated on 2019-12-26: 51 Biggest Movers From Tuesday

Financial news for OCUL dated on 2019-12-02: 52 Biggest Movers From Friday

Financial news for OCUL dated on 2019-11-29: 35 Stocks Moving In Friday's Mid-Day Session

Financial news for OCUL dated on 2019-11-29: 52 Biggest Movers From Wednesday

Financial news for OCUL dated on 2019-11-15: 10 Biggest Price Target Changes For Friday

Financial news for OCUL dated on 2019-11-15: H.C. Wainwright Maintains Buy on Ocular Therapeutix, Lowers Price Target to \$6

Financial news for OCUL dated on 2019-11-13: JMP Securities Maintains Market Outperform on Ocular Therapeutix, Lowers Price Target to \$7

Financial news for OCUL dated on 2019-11-13: 74 Biggest Movers From Yesterday

Financial news for OCUL dated on 2019-11-12: Ocular Therapeutix Q3 EPS \$(0.45) Beats \$(0.47) Estimate, Sales \$829K Beat \$580K Estimate

Financial news for OCUL dated on 2019-11-12: The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat

Financial news for OCUL dated on 2019-11-12: 58 Biggest Movers From Yesterday

Financial news for OCUL dated on 2019-11-11: 38 Stocks Moving In Monday's Mid-Day Session

Financial news for OCUL dated on 2019-11-08: Ocular Therapeutix Inc To Allocate Capital And Resources To Maximize Commercial Opportunity Of Dextenza

Financial news for OCUL dated on 2019-11-08: Ocular Therapeutix Announces Strategic Update And Operational Restructuring; Plan Is Expected To Result In \$11M In Annualized Savings

Financial news for OCUL dated on 2019-10-01: Ocular Therapeutix Announces Permanent J-Code For DEXTENZA Effective October 1, 2019

Financial news for OCUL dated on 2019-09-27: 50 Biggest Movers From Yesterday

Financial news for OCUL dated on 2019-09-24: Ocular Therapeutix Announces First Patient Dosed In Phase 3 Clinical Trial Of Dextenza For The Treatment Of Allergic Conjunctivitis

Financial news for OCUL dated on 2019-08-27: 50 Biggest Movers From Yesterday

Financial news for OCUL dated on 2019-08-12: Ocular Therapeutix Option Alert: Mar 20 \$5 Calls Sweep (2) near the Ask: 500 @ \$1.101 vs 235 OI; Ref=\$4.28

Financial news for OCUL dated on 2019-08-09: 110 Biggest Movers From Yesterday

Financial news for OCUL dated on 2019-08-08: 90 Stocks Moving In Thursday's Mid-Day Session

Financial news for OCUL dated on 2019-08-08: Ocular Therapeutix shares are trading lower after the company reported worse-than-expected Q2 EPS and sales results.

Financial news for OCUL dated on 2019-08-08: 25 Healthcare Stocks Moving In Today's Pre-Market Session

Financial news for OCUL dated on 2019-08-07: 42 Healthcare Stocks Moving In Wednesday's After-Market Session

Financial news for OCUL dated on 2019-08-07: Ocular Therapeutix Q2 EPS \$(0.57) Misses \$(0.48) Estimate, Sales \$650 Miss \$740K Estimate

Financial news for OCUL dated on 2019-08-02: 40 Healthcare Stocks Moving In Thursday's After-Market Session

Financial news for OCUL dated on 2019-07-31: 28 Healthcare Stocks Moving In Today's Pre-Market Session

Financial news for OCUL dated on 2019-07-30: 45 Healthcare Stocks Moving In Monday's After-Market Session

Financial news for OCUL dated on 2019-07-29: 62 Biggest Movers From Friday

Financial news for OCUL dated on 2019-07-26: 28 Healthcare Stocks Moving In Today's Pre-Market Session

Financial news for OCUL dated on 2019-07-26: Ocular Therapeutix Reports Early Assignment Of Permanent, Specific J-Code (J1096) For DEXTENZA 0.4mg

Financial news for OCUL dated on 2019-07-08: 33 Biggest Movers From Friday

Financial news for OCUL dated on 2019-07-05: 24 Stocks Moving In Friday's Mid-Day Session

Financial news for OCUL dated on 2019-07-02: 32 Stocks Moving In Tuesday's Pre-Market Session

Financial news for OCUL dated on 2019-07-01: Ocular Therapeutix Announces the Commercial Launch of DEXTENZA in the United States

Financial news for OCUL dated on 2019-06-24: 68 Biggest Movers From Friday

Financial news for OCUL dated on 2019-06-23: Bulls And Bears Of The Week: Tyson, Tesla, Crocs And More

Financial news for OCUL dated on 2019-06-21: 44 Stocks Moving In Friday's Mid-Day Session

Financial news for OCUL dated on 2019-06-21: FDA OKs Expanded Indication For Ocular Therapeutix Eye Pain Drug Months Ahead Of Schedule

Financial news for OCUL dated on 2019-06-21: Ocular Therapeutix shares are trading higher after the company received FDA approval of its sNDA for DEXTENZA for treatment of ocular inflammation following ophthalmic surgery.

Financial news for OCUL dated on 2019-06-21: Ocular Therapeutix Announces FDA Approval Of Supplemental New Drug Application For DEXTENZA For Treatment Of Ocular Inflammation Following Ophthalmic Surgery

Financial news for OCUL dated on 2019-06-19: 48 Biggest Movers From Yesterday

Financial news for OCUL dated on 2019-06-18: 40 Stocks Moving In Tuesday's Mid-Day Session

Financial news for OCUL dated on 2019-06-14: 54 Biggest Movers From Yesterday

Financial news for OCUL dated on 2019-06-12: 66 Biggest Movers From Yesterday

Financial news for OCUL dated on 2019-06-11: Social Media Posts Draw Attention To Recent Ocular Therapeutix Buys Ahead Of July 1st 'Soft Launch'

Financial news for OCUL dated on 2019-06-11: Ocular Therapeutics shares are trading higher potentially on trader optimism after a recent cluster of insider buying from management.

Financial news for OCUL dated on 2019-06-11: 48 Stocks Moving In Tuesday's Mid-Day Session

Financial news for OCUL dated on 2019-06-10: 60 Biggest Movers From Friday

Financial news for OCUL dated on 2019-06-07: 44 Stocks Moving In Friday's Mid-Day Session

Financial news for OCUL dated on 2019-06-03: 64 Biggest Movers From Friday

Financial news for OCUL dated on 2019-05-29: Ocular Therapeutix Announces Receipt Of New Reimbursement Code (C-Code) And Pass-Through Payment Status For DEXTENZA

Financial news for OCUL dated on 2019-05-22: The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study

Financial news for OCUL dated on 2019-05-22: 50 Biggest Movers From Yesterday

Financial news for OCUL dated on 2019-05-21: Mid-Afternoon Market Update: Dycom Industries Rises On Upbeat Q1 Results; BioCryst Pharmaceuticals Shares Plummet

Financial news for OCUL dated on 2019-05-21: Raymond James Downgrades Ocular Therapeutix, Remains Bullish On Pipeline

Financial news for OCUL dated on 2019-05-21: 36 Stocks Moving In Tuesday's Mid-Day Session

Financial news for OCUL dated on 2019-05-21: Mid-Day Market Update: CIRCOR Jumps Following \$45/Share Bid From Crane; Ocular Therapeutix Shares Slide

Financial news for OCUL dated on 2019-05-21: Mid-Morning Market Update: Markets Open Higher; TJX Earnings Top Estimates

Financial news for OCUL dated on 2019-05-21: Benzinga's Top Upgrades, Downgrades For May 21, 2019

Financial news for OCUL dated on 2019-05-21: Ocular Therapeutix shares are trading lower after the company reported its Phase 3 trial of OTX-TP for glaucoma treatment did not meet its primary endpoint. Cowen and Raymond James downgraded the stock.

Financial news for OCUL dated on 2019-05-21: 28 Stocks Moving In Tuesday's Pre-Market Session

Financial news for OCUL dated on 2019-05-21: The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails

Financial news for OCUL dated on 2019-05-21: Raymond James Downgrades Ocular Therapeutix, Inc. - Common Stock to Outperform

Financial news for OCUL dated on 2019-05-21: Cowen & Co. Downgrades Ocular Therapeutix, Inc. - Common Stock to Market Perform

Financial news for OCUL dated on 2019-05-20: Ocular Therapeutix shares are trading lower after the company reported its Phase 3 trial of OTX-TP for treatment of glaucoma did not meet its primary endpoint.

Financial news for OCUL dated on 2019-05-20: Ocular Therapeutix Shares Resume Trade, Fall ~24%

Financial news for OCUL dated on 2019-05-20: Ocular Therapeutix Shares To Resume Trade At 4:35 p.m. EDT

Financial news for OCUL dated on 2019-05-20: Ocular Therapeutix Says Phase 3 Trial OF OTX-TP For Treatment Of Glaucoma Did Not Meet Primary Endpoint

Financial news for OCUL dated on 2019-05-20: Ocular Therapeutix Shares Halted News Pending

Financial news for OCUL dated on 2019-05-10: The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales

Financial news for OCUL dated on 2019-05-10: Ocular Therapeutix Q1 EPS \$(0.41) Beats \$(0.42) Estimate, Sales \$492K Beat \$430K Estimate

Financial news for OCUL dated on 2019-05-01: Ocular Therapeutix Announces DEXTENZA Recommended For Unique J-Code By CMS

Financial news for OCUL dated on 2019-04-30: Ocular Therapeutix, Inc. Settles Litigation With Mati Therapeutics, Inc.

Financial news for OCUL dated on 2019-04-24: Ocular Therapeutix Highlights Presentation Of New Data At Association for Research in Vision and Ophthalmology Annual Meeting

Financial news for OCUL dated on 2019-04-08: 5 Stocks To Watch For April 8, 2019

Financial news for OCUL dated on 2019-04-05: Ocular Therapeutix Filing Shows Registration For \$50M Common Stock Offering

Financial news for OCUL dated on 2019-04-02: UPDATE: Ocular Therapeutix Reports PDUFA Date Set For Nov. 10, 2019

Financial news for OCUL dated on 2019-04-02: Ocular Therapeutix Reports Notification Of FDA Acceptance Of Supplemental New Drug Submission For DEXTENZA For Treatment of Ocular Inflammation Following Ophthalmic Surgery

Financial news for OCUL dated on 2019-04-01: Ocular Therapeutix Filing Shows Registration For ~9.57M Share Common Stock Offering Via Selling Shareholders

Financial news for OCUL dated on 2019-03-07: Ocular Therapeutix Q4 EPS \$(0.42) Misses \$(0.38) Estimate, Sales \$504K Beat \$480K Estimate

Financial news for OCUL dated on 2019-03-07: Daily Biotech Pulse: Allergan's Depression Drug Flunks Late-Stage Trial, Apellis Offering, ShockWave Medical IPO

Financial news for OCUL dated on 2019-03-04: Ocular Therapeutix 13D Filing From Summer Road Shows Raised Stake From ~3.78M Shares To ~9.57M Shares, Or 17.8% Stake

Financial news for OCUL dated on 2019-03-03: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

Financial news for OCUL dated on 2019-02-26: 72 Biggest Movers From Yesterday

Financial news for OCUL dated on 2019-02-25: 42 Stocks Moving In Monday's Mid-Day Session

Financial news for OCUL dated on 2019-02-25: 71 Biggest Movers From Friday

Financial news for OCUL dated on 2019-02-22: Ocular Therapeutix shares are trading higher after the company priced a \$37.5 million convertible debt financing with an

accredited investor, minimizing dilution and raising the company cash position by over 60%.

Financial news for OCUL dated on 2019-02-20: Ocular Therapeutix Reports Dosing Of First Patient In OTX-TKI Phase 1 Trial For Treatment Of Wet AMD

Financial news for OCUL dated on 2019-02-13: Ocular Therapeutix Shares Tick Slightly Lower As Traders Circulating Unconfirmed Word Of FDA Warning Letter

Financial news for OCUL dated on 2019-01-24: Stocks Which Set New 52-Week Low Yesterday, Jan. 24, 2019

Financial news for OCUL dated on 2019-01-11: The Daily Biotech Pulse: Agile Gives Regulatory Update On Contraceptive Patch, Advaxis Misses Estimates, Ocular Submits sNDA

Financial news for OCUL dated on 2019-01-10: Ocular Therapeutix Submits Supplemental New Drug Application For DEXTENZA For Treatment Of Ocular Inflammation Following Ophthalmic Surgery

Financial news for OCUL dated on 2019-01-07: Purdue Pharma L.P. And Ocular Therapeutix, Inc. Announce Initiation Of Collaborative Research Activities To Evaluate Innovative Formulations For Non-Opioid Treatments For Pain

Financial news for OCUL dated on 2018-12-31: 33 Stocks Moving In Monday's Mid-Day Session

Financial news for OCUL dated on 2018-12-31: 5 Stocks To Watch For December 31, 2018

Financial news for OCUL dated on 2018-12-28: Ocular Therapeutix Filing Shows Registration For \$200M Mixed Securities Offering

Financial news for OCUL dated on 2018-12-04: 56 Biggest Movers From Yesterday

Financial news for OCUL dated on 2018-12-03: 46 Stocks Moving In Monday's Mid-Day Session

Financial news for OCUL dated on 2018-12-03: Mid-Morning Market Update: Markets Open Higher; Nexstar to buy Tribune Media for \$46.50/Share

Financial news for OCUL dated on 2018-12-03: Cantor Fitzgerald Reiterates Overweight Rating On Ocular Therapeutics Following FDA Approval Of DEXTENZA; Firm Says Following Approval, Co. Can Now Shift Focus To Commercialization Efforts

Financial news for OCUL dated on 2018-12-03: Ocular Therapeutix Shares Resume Trading

Financial news for OCUL dated on 2018-12-03: Ocular Therapeutix Announces FDA Approval of DEXTENZA

Financial news for OCUL dated on 2018-12-03: 52 Biggest Movers From Friday

Financial news for OCUL dated on 2018-11-30: Ocular Therapeutix Shares Halted News Pending

Financial news for OCUL dated on 2018-11-30: Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates

Financial news for OCUL dated on 2018-11-30: 38 Stocks Moving In Friday's Mid-Day Session

Financial news for OCUL dated on 2018-11-08: The Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering

Financial news for OCUL dated on 2018-11-07: Ocular Therapeutix Q3 EPS \$(0.38), Inline, Sales \$498K Beat \$470K Estimate

Financial news for OCUL dated on 2018-10-19: Ocular Therapeutix Receives FDA Warning Letter Related To ReSure Sealant; Letter Relates To Co.'s Compliance With Data Collection And Information Reporting, Co. Says Working To Address And Resolve Concerns

Financial news for OCUL dated on 2018-08-07: Ocular Therapeutix Q2 GAAP EPS \$(0.37) May Not Compare To \$(0.38) Estimate, Sales \$648K Beat \$380K Estimate

Financial news for OCUL dated on 2018-08-07: The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmmed's Antibiotic Faces FDA Panel

Financial news for OCUL dated on 2018-07-19: Ocular Therapeutix Reports FDA Acceptance Of New Drug Application Resubmission For DEXTENZA; PDUFA Date Set For Dec.

28, 2018

Financial news for OCUL dated on 2018-07-02: 38 Stocks Moving In Monday's Mid-Day Session

Financial news for OCUL dated on 2018-06-29: '\$OCUL needed one full year to correct manufacturing issues and resubmit. Good reminder that CMC stuff matters.' -Tweet From STAT News' Adam Feuerstein

Financial news for OCUL dated on 2018-06-29: '\$OCUL needed one full year to correct manufacturing issues and resubmit. Good reminder that CMC stuff matters.'-STAT's Adam Feuerstein Tweets

Financial news for OCUL dated on 2018-06-29: Ocular Therapeutix Reports New Drug Application Resubmission Of DEXTENZA

Financial news for OCUL dated on 2018-05-08: Ocular Therapeutix Shares Down 10.7% After Hours Following Q1 Miss

Financial news for OCUL dated on 2018-05-08: Ocular Therapeutix Q1 EPS \$(0.40) Misses \$(0.38) Estimate, Sales \$340K Miss \$450K Estimate

Financial news for OCUL dated on 2018-05-08: Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure

Financial news for OCUL dated on 2018-05-06: The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Financial news for OCUL dated on 2018-05-03: Ocular Therapeutix Treats 1st Patient in Phase 1 Clinical Trial of OTX-TIC

Financial news for OCUL dated on 2018-03-08: Ocular Therapeutix Reports Q4 EPS \$(0.44) vs \$(0.52) Est., \$487K vs \$520K Est.

Financial news for OCUL dated on 2018-03-02: The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Financial news for OCUL dated on 2018-01-26: 44 Biggest Movers From Yesterday

Financial news for OCUL dated on 2018-01-25: 34 Stocks Moving In Thursday's Mid-Day Session

Financial news for OCUL dated on 2018-01-25: Benzinga Pro's 4 Stocks To Watch Today

Financial news for OCUL dated on 2018-01-25: Ocular TherapeutixTM Prices 6.5M Share Offering At \$5/Share

Financial news for OCUL dated on 2018-01-25: 26 Stocks Moving In Thursday's Pre-Market Session

Financial news for OCUL dated on 2018-01-25: A Peek Into The Markets: U.S. Stock Futures Gain Ahead Of Earnings, Economic Data

Financial news for OCUL dated on 2018-01-25: 12 Stocks To Watch For January 25, 2018

Financial news for OCUL dated on 2018-01-24: 11 Stocks Moving In Wednesday's After-Hours Session

Financial news for OCUL dated on 2018-01-24: Ocular Therapeutix Announces Common Stock Offering, No Size Disclosed

Financial news for OCUL dated on 2018-01-22: 34 Biggest Movers From Friday

Financial news for OCUL dated on 2018-01-19: 28 Stocks Moving In Friday's Mid-Day Session

Financial news for OCUL dated on 2018-01-19: Benzinga's Top Upgrades, Downgrades For January 19, 2018

Financial news for OCUL dated on 2018-01-19: 14 Stocks Moving In Friday's Pre-Market Session

Financial news for OCUL dated on 2018-01-19: BTIG Research Upgrades Ocular Therapeutix to Buy

Financial news for OCUL dated on 2018-01-16: 38 Biggest Movers From Friday

Financial news for OCUL dated on 2017-12-22: Ocular Therapeutix Gives Update On Current Legal Proceedings, Says Co. Received A Subpoena Requesting Documents And Info

Concerning DEXTENZA Including Communications With The FDA, Investors, And Others

Financial news for OCUL dated on 2017-11-07: Ocular Therapeutix Reports Q3 EPS \$(0.54) vs \$(0.53) Est., Sales \$523K vs \$510K Est.

Financial news for OCUL dated on 2017-10-24: Guggenheim Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces \$12.00 Price Target

Financial news for OCUL dated on 2017-09-25: Ocular Therapeutix Names Donald Notman CFO

Financial news for OCUL dated on 2017-09-11: Morgan Stanley Healthcare Conference Begins Today, Presenters Include: Veeva Systems, Quorum Health, Neurocrine Biosciences, Vertex Pharma, Merck, Ocular Therapeutix, Biogen, Gilead, and Bristol-Myers

Financial news for OCUL dated on 2017-09-08: Ocular Therapeutix Names Dr. Michael Goldstein As Chief Medical Officer

Financial news for OCUL dated on 2017-08-08: Ocular Therapeutix Reports Q2 GAAP EPS \$(0.64) May Not Compare To \$(0.56) Est., Sales \$438K

Financial news for OCUL dated on 2017-08-01: Ocular Therapeutix Names Antony Mattessich CEO

Financial news for OCUL dated on 2017-08-01: August PDUFA Dates: Biotech Investors Stay Tuned To A Month Of Plenty

Financial news for OCUL dated on 2017-07-26: Benzinga's Top Upgrades, Downgrades For July 26, 2017

Financial news for OCUL dated on 2017-07-26: H.C. Wainwright Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces \$10.00 Price Target

Financial news for OCUL dated on 2017-07-14: Adam Feuerstein Tweets: \$OCUL straphangers should read this Seeking Alpha story on hidden risk in glaucoma ph3 study --> seekingalpha.com/article/408774... Changed ph3 endpoint

Financial news for OCUL dated on 2017-07-12: Mid-Afternoon Market Update: NASDAQ Up Over 1%; MSC Industrial Shares Plummet

Financial news for OCUL dated on 2017-07-12: 10 Biggest Mid-Day Losers For Wednesday

Financial news for OCUL dated on 2017-07-12: Mid-Day Market Update: Ocular Therapeutix Drops After Major Setback In Dextenza; I.D. Systems Shares Surge

Financial news for OCUL dated on 2017-07-12: Adam Feuerstein Tweets: Amazed \$OCUL down just 20% to \$6. If they can't manufacture Dextenza, hopes for future glaucoma product should lie shattered on floor.

Financial news for OCUL dated on 2017-07-12: Cantor Remains Confident On Ocular Therapeutix Despite Big Decline

Financial news for OCUL dated on 2017-07-12: Ocular Therapeutix Falls 30% After Major Setback In Dextenza

Financial news for OCUL dated on 2017-07-12: Ocular Therapeutix Shares Down 32.8% In Pre-Market Following Tuesday Report Of CRL Received From FDA For DEXTENZA NDA

Financial news for OCUL dated on 2017-07-12: 22 Stocks Moving In Wednesday's Pre-Market Session

Financial news for OCUL dated on 2017-07-11: Ocular Therapeutix Shares To Resume Trade At 5:30 p.m. EDT

Financial news for OCUL dated on 2017-07-11: Ocular Therapeutix Reports Received CRL From FDA For DEXTENZA NDA

Financial news for OCUL dated on 2017-07-11: Ocular Therapeutics Shares Halted News Pending

Financial news for OCUL dated on 2017-07-11: 12 Biggest Mid-Day Gainers For Tuesday

Financial news for OCUL dated on 2017-07-11: Ocular Therapeutix Shares Up 20.8% Following Monday Submission Of Amendment To Potentially Extend Review For DEXTENZA NDA

Financial news for OCUL dated on 2017-07-11: 20 Stocks Moving In Tuesday's Pre-Market Session

Financial news for OCUL dated on 2017-07-10: Ocular Therapeutix Reports Submission Of Amendment To Potentially Extend Review For DEXTENZA NDA

Financial news for OCUL dated on 2017-07-10: 12 Biggest Mid-Day Losers For Monday

Financial news for OCUL dated on 2017-07-10: 22 Stocks Moving In Monday's Pre-Market Session

Financial news for OCUL dated on 2017-07-07: Adam Feuerstein Reports 'Ocular Therapeutix still working on manufacturing fix for eye drug with FDA deadline approaching'

Financial news for OCUL dated on 2017-07-07: 15 Biggest Mid-Day Losers For Friday

Financial news for OCUL dated on 2017-07-07: 20 Stocks Moving In Friday's Pre-Market Session

Financial news for OCUL dated on 2017-07-06: Adam Feuerstein Tweets: \$OCUL FDA approval imperiled by drug contamination concerns --> statnews.com/2017/07/06/ocu... Aluminum contaminating Dextenza batches.

Financial news for OCUL dated on 2017-07-05: Attention Biotech Investors: Keep Your Date With July PDUFA Action-Days

Financial news for OCUL dated on 2017-06-23: 12 Biggest Mid-Day Losers For Friday

Financial news for OCUL dated on 2017-06-23: Mid-Morning Market Update: Markets Mostly Flat; BlackBerry Sales Miss Views

Financial news for OCUL dated on 2017-06-23: Benzinga's Top Upgrades, Downgrades For June 23, 2017

Financial news for OCUL dated on 2017-06-23: The Market In 5 Minutes

Financial news for OCUL dated on 2017-06-23: 20 Stocks Moving In Friday's Pre-Market Session

Financial news for OCUL dated on 2017-06-23: Morgan Stanley Downgrades Ocular Therapeutix to Equal-Weight

Financial news for OCUL dated on 2017-06-22: Ocular Therapeutix Announces Amar Sawhney To Transition To Sole Role Of Chair, Antony Mattessich To Succeed Sawhney As CEO

Financial news for OCUL dated on 2017-06-15: Dear Avi: Should I Buy An IPO?

Financial news for OCUL dated on 2017-06-09: Jefferies Health Care Conference Concludes Today, Presenters Include: Mazor Robotic, bluebird bio, and Ocular Therapeutix

Financial news for OCUL dated on 2017-05-11: Ocular Therapeutix Reports FDA Has Set July 19 PDUFA Date For DEXTENZA NDA

Financial news for OCUL dated on 2017-05-09: Ocular Therapeutix Offers Preclinical Data on Pharmacokinetics, Efficacy, Tolerability of OTX-TKI at ARVO Annual Meeting

Financial news for OCUL dated on 2017-05-08: Ocular Therapeutix's Manufacturing Inspection: Items Of Concern Are 'Addressable,' Shouldn't Delay Product Launch

Financial news for OCUL dated on 2017-05-08: UPDATE: Ocular Therapeutix Says FDA Set PDUFA Date of Jul. 19, 2017

Financial news for OCUL dated on 2017-05-08: Ocular Therapeutix Reports Presentation of Added Data from Most Recent Phase 3 Study Evaluating Safety, Efficacy of DEXTENZA 0.4 mg for Treatment of Ocular Pain, Inflammation Following Cataract Surgery

Financial news for OCUL dated on 2017-05-05: BTIG Research Downgrades Ocular Therapeutix to Neutral

Financial news for OCUL dated on 2017-05-05: Ocular Therapeutix Reports Q1 EPS \$(0.58) vs \$(0.48) Est., Sales \$475K vs \$470K Est.

Financial news for OCUL dated on 2017-04-06: Ocular Therapeutix Names George Migausky Interim CFO

Financial news for OCUL dated on 2017-03-20: Ocular Therapeutix CFO Bradford Smith To Resign

Financial news for OCUL dated on 2017-03-17: 20 Biggest Mid-Day Losers For Friday

Financial news for OCUL dated on 2017-03-17: 20 Stocks Moving In Friday's Pre-Market Session

Financial news for OCUL dated on 2017-03-15: Ocular Therapeutix Issues Press Release Discussing Intent for Study with DEXTENZA, Offers 4 Bullets Describing Patient's Experience During Study

Financial news for OCUL dated on 2017-03-10: Ocular Therapeutix Reports Q4 EPS \$(0.52) vs \$(0.45) Est., Sales \$511K vs \$490K Est.

Financial news for OCUL dated on 2017-03-07: Cowen Annual Healthcare Conference Continues Today; Presenters Include Regulus, Eli Lilly, Oculus, DexCom, Illumina, Allergan, Kite Pharma, Pfizer, and bluebird bio

Financial news for OCUL dated on 2017-02-23: RBC Capital Markets Healthcare Conference Concludes Today; Presenters Include Spark Therapeutics, Johnson & Johnson, HCA Holdings, Ocular Therapeutix, Valeant & Agile Therapeutics

Financial news for OCUL dated on 2017-02-22: Ocular Therapeutix Reports FDA Acceptance of NDA Resubmission for DEXTENZA

Financial news for OCUL dated on 2017-02-21: Ocular Sciences Falls to Low of \$9.66 on Volume

Financial news for OCUL dated on 2017-02-13: Bio CEO & Investor Conference Begins Today; Presenters Include Inovio Pharmaceuticals, Agile Therapeutics, CytRx, Eiger Biopharmaceuticals, Neurotrope, & Ocular Therapeutix

Financial news for OCUL dated on 2017-02-10: 20 Biggest Mid-Day Gainers For Friday

Financial news for OCUL dated on 2017-02-10: Benzinga's Top Upgrades, Downgrades For February 10, 2017

Financial news for OCUL dated on 2017-02-10: Cantor Fitzgerald Initiates Coverage On Ocular Therapeutix At Overweight, Announces \$35 Price Target

Financial news for OCUL dated on 2017-02-10: 30 Stocks Moving In Friday's Pre-Market Session

Financial news for OCUL dated on 2017-01-24: 15 Biggest Mid-Day Losers For Tuesday

Financial news for OCUL dated on 2017-01-24: Ocular Therapeutix Lower After 3.5 Million Share Offering

Financial news for OCUL dated on 2017-01-24: Mid-Day Market Update: Genvec Jumps Following Announcement of Acquisition By Intrexon; BT Group Shares Drop

Financial news for OCUL dated on 2017-01-24: Mid-Morning Market Update: Markets Open Higher; Verizon Earnings Miss Expectations

Financial news for OCUL dated on 2017-01-24: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for OCUL dated on 2017-01-24: Ocular Therapeutic Prices 3.5M Shares At \$7/Share

Financial news for OCUL dated on 2017-01-23: Ocular Therapeutix Reports Offering of \$25M in Common Shares

Financial news for OCUL dated on 2017-01-23: 8-K from Ocular Therapeutix Shows Co. Resubmitted NDA to FDA For DEXTENZA 0.4 mg for Treatment of Ocular Pain Occurring After Ophthalmic Surgery

Financial news for OCUL dated on 2017-01-23: Ocular Therapeutix Resubmits NDA for DEXTENZA For Ocular Pain Treatment Following Ophthalmic Surgery

Financial news for OCUL dated on 2017-01-04: Technical Alert: Ocular Therapeutix Higher Off Positive Data

Financial news for OCUL dated on 2017-01-04: Ocular Therapeutix Reports Statistically Significant Secondary Endpoint Of Absence Of Ocular Flare Confirms Further Evidence Of Reduction Of Inflammation

Financial news for OCUL dated on 2016-12-19: 15 Biggest Mid-Day Gainers For Monday

Financial news for OCUL dated on 2016-11-30: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for OCUL dated on 2016-11-29: 20 Stocks Moving In Tuesday's Pre-Market Session

Financial news for OCUL dated on 2016-11-28: 12 Biggest Mid-Day Losers For Monday

Financial news for OCUL dated on 2016-11-28: 16 Stocks Moving In Monday's Pre-Market Session

Financial news for OCUL dated on 2016-11-21: Technical Alert: Ocular Therapeutix Finds Support And Resistance

Financial news for OCUL dated on 2016-11-21: 15 Stocks Moving In Monday's Pre-Market Session

Financial news for OCUL dated on 2016-11-18: Ocular Therapeutics Spikes to High of \$10.14 on Volume

Financial news for OCUL dated on 2016-11-16: Ocular Therapeutix Higher For Seventh Day In A Row

Financial news for OCUL dated on 2016-11-14: 18 Biggest Mid-Day Gainers For Monday

Financial news for OCUL dated on 2016-11-14: Ocular Therapeutix Higher Off Positive Results For Dextenza

Financial news for OCUL dated on 2016-11-14: 18 Stocks Moving In Monday's Pre-Market Session

Financial news for OCUL dated on 2016-11-14: Ocular Therapeutix Announces Successful Topline Results for Both Inflammation and Pain Primary Efficacy Endpoints from Phase 3 Clinical Trial of DEXTENZA, Met Both Primary Endpoints

Financial news for OCUL dated on 2016-11-09: Ocular Therapeutix Reports Q3 EPS \$(0.39) vs. Est. \$(0.50), Rev. \$477K vs. Est. \$470K

Financial news for OCUL dated on 2016-10-13: Deal With Regeneron Means Validation For Ocular Therapeutix

Financial news for OCUL dated on 2016-10-13: Mid-Afternoon Market Update: Lindsay Gains Following Q4 Results; Fluidigm Shares Drop

Financial news for OCUL dated on 2016-10-13: Technical Alert: Ocular Therapeutix Pares Early Gains

Financial news for OCUL dated on 2016-10-13: 10 Biggest Mid-Day Gainers For Thursday

Financial news for OCUL dated on 2016-10-13: Mid-Day Market Update: Ocular Therapeutix Surges Following Collaboration Deal With Regeneron; Flex Pharma Shares Slide

Financial news for OCUL dated on 2016-10-13: Mid-Morning Market Update: Markets Open Lower; Delta Air Lines Profit Beats Estimates

Financial news for OCUL dated on 2016-10-13: Ocular Therapeutix Shares Charge Higher Following Collaboration Deal With Regeneron

Financial news for OCUL dated on 2016-10-13: 18 Stocks Moving In Thursday's Pre-Market Session

Financial news for OCUL dated on 2016-10-13: Ocular Therapeutix Shares to Resume Trade at 7:30 a.m. EDT

Financial news for OCUL dated on 2016-10-13: UPDATE: Ocular Therapeutix Will Receive up to \$305M in Milestone Payments in Addition to Royalties on Potential Future Net Sales

Financial news for OCUL dated on 2016-10-13: Ocular Therapeutix, Regeneron Report Entering Into of Strategic Collaboration for Developing Sustained Release Formulation of Aflibercept for Treatment of Wet AMD, Other Serious Retinal Diseases

Financial news for OCUL dated on 2016-10-04: Ocular Therapeutix Begins Enrollment in First Phase 3 Clinical Trial with OTX-TP for the Treatment of Glaucoma and Ocular Hypertension

Financial news for OCUL dated on 2016-08-16: 20 Biggest Mid-Day Losers For Tuesday

Financial news for OCUL dated on 2016-08-16: 20 Stocks Moving In Tuesday's Pre-Market Session

Financial news for OCUL dated on 2016-08-15: 15 Biggest Mid-Day Gainers For Monday

Financial news for OCUL dated on 2016-08-15: 12 Stocks Moving In Monday's Pre-Market Session

Financial news for OCUL dated on 2016-08-15: Ocular Therapeutix +12% Premarket @ \$7.60

Financial news for OCUL dated on 2016-08-12: 18 Biggest Mid-Day Gainers For Friday

Financial news for OCUL dated on 2016-08-12: 18 Stocks Moving In Friday's Pre-Market Session

Financial news for OCUL dated on 2016-08-11: 18 Biggest Mid-Day Gainers For Thursday

Financial news for OCUL dated on 2016-08-11: Benzinga's Top Initiations

Financial news for OCUL dated on 2016-08-11: 22 Stocks Moving In Thursday's Pre-Market Session

Financial news for OCUL dated on 2016-08-11: JMP Securities Initiates Coverage on Ocular Therapeutix at Outperform

Financial news for OCUL dated on 2016-08-09: Ocular Therapeutix Reports Q2 EPS \$(0.46) vs \$(0.49) Est., Sales \$441K vs \$550K Est.

Financial news for OCUL dated on 2016-08-08: A Handful of Biotech Stocks Plunge After Disappointing Results

Financial news for OCUL dated on 2016-08-08: 11 Stocks Moving In Monday's Pre-Market Session

Financial news for OCUL dated on 2016-08-04: 20 Biggest Mid-Day Gainers For Thursday

Financial news for OCUL dated on 2016-08-04: Mid-Morning Market Update: Markets Edge Lower; Viacom Tops Q3 Expectations

Financial news for OCUL dated on 2016-08-04: 20 Stocks Moving In Thursday's Pre-Market Session

Financial news for OCUL dated on 2016-08-04: Ocular Therapeutix +26% Premarket @ \$5.29; FDA Said Corrective Actions Received in Response to CRL Appear to Mostly Address the Ten inspectional Observations Raised in Form FDA 483

Financial news for OCUL dated on 2016-08-03: After-Hours Gainers Aug. 3, '16: OCUL Up 22%, SQ 14.9%, CBMX 13.5%, AXGN 10%, AVID 8.7%, PODD 8.6%, NSTG 8.3%, JACK 8%, EXEL 7.7%

Financial news for OCUL dated on 2016-08-03: Ocular Therapeutix Receives CRL On NDA For DEXTENZA Due To One Outstanding Item Pertaining To Manufacturing Process And Controls

Financial news for OCUL dated on 2016-08-03: Ocular Therapeutix Provides Update on NDA for Dextenza; FDA Says Corrective Actions Receive in Response to CRL Appear to Address the Ten inspectional Observations Raised in Form FDA 483 With One Exception

Financial news for OCUL dated on 2016-07-25: 10 Biggest Mid-Day Losers For Monday

Financial news for OCUL dated on 2016-07-25: Ocular Therapeutix Gets Complete Response Letter From FDA For Its NDA For DEXTENZA

Financial news for OCUL dated on 2016-07-25: 13 Stocks Moving In Monday's Pre-Market Session

Financial news for OCUL dated on 2016-07-25: Ocular Therapeutix Receives CRL from FDA for its NDA for DEXTENZA for the Treatment of Post-Surgical Ocular Pain, No Efficacy Or Safety Issues Raised By FDA; Outstanding Items Due To Manufacturing Process & Controls

Financial news for OCUL dated on 2016-07-08: Jennison Associates Reports 12% Passive Stake in Ocular Therapeutix in 13G

Financial news for OCUL dated on 2016-06-06: Cowen Says Ocular Therapeutix's OTX-DP Miss 'Meaningless' To Bull Thesis

Financial news for OCUL dated on 2016-06-06: Monday's 7 Biggest Mid-Day Losers

Financial news for OCUL dated on 2016-06-06: Mid-Day Market Update: Dow Surges Over

100 Points; Adamis Pharmaceuticals Shares Slide

Financial news for OCUL dated on 2016-06-06: UPDATE: Cowen on Ocular Therapeutix: 'Although any clinical trial failure of any kind is always a disappointment, in this instance, the OTX-DP miss in allergic conjunctivitis is meaningless to our thesis.'

Financial news for OCUL dated on 2016-06-06: Oculus Therapeutix Shares Edge Slightly Higher Over Last Few Mins as Hearing Cowen Has Issued Mid-Day Note Reiterating Buy, \$60 Target

Financial news for OCUL dated on 2016-06-06: These 3 Biotech Stocks Are Getting Killed Today

Financial news for OCUL dated on 2016-06-06: Mid-Morning Market Update: Markets Open Higher; Devon Energy To Sell Non-Core Upstream Assets For Around \$1 Billion

Financial news for OCUL dated on 2016-06-06: 10 Stocks Moving In Monday's Pre-Market Session

Financial news for OCUL dated on 2016-06-06: Ocular Therapeutics, ProNai Therapeutics To Resume Trade At 7:30am ET

Financial news for OCUL dated on 2016-06-06: UPDATE: Ocular Therapeutix Reports Phase 3 Clinical Trial Of DEXTENZA For Allergic Conjunctivitis; Did Not Meet Primary Endpoint, Conf. Call At 8:30am ET Today

Financial news for OCUL dated on 2016-06-06: Ocular Therapeutics Phase 3 DEXTENZA Clinical Trial Did Not Meet Primary Endpoint

Financial news for OCUL dated on 2016-05-10: Ocular Therapeutix Reports Q1 EPS \$(0.44) vs. Est. \$(0.43)

Financial news for OCUL dated on 2016-04-27: Ocular Therapeutix Reports Closing of End of Phase 2 Review with FDA for OTX-TP for Glaucoma, Ocular Hypertension

Financial news for OCUL dated on 2016-03-10: Ocular TherapeutixTM Reports Q4 EPS \$(0.43) vs. Est. \$(0.47)

Financial news for OCUL dated on 2016-02-18: Morgan Stanley Upgrades Ocular Therapeutix to Overweight, Maintains \$15.00 PT

Financial news for OCUL dated on 2016-02-17: Ocular Therapeutix Spikes 45% On Drug News; Morgan Stanley Upgraded Co. To Overweight

Financial news for OCUL dated on 2016-02-17: Morgan Stanley Upgrades Ocular Therapeutix Following Guidance For A Pathway Forward With OTX-TP

Financial news for OCUL dated on 2016-02-17: Morgan Stanley Upgrades Ocular Therapeutix to Overweight, Maintains \$15.00 PT

Financial news for OCUL dated on 2016-02-16: Oculus Therapeutix Announces Phase 3 Clinical Development Plan, First 2 Planned Phase 3 Clinical Trials To Commence In Q3 2016

Financial news for OCUL dated on 2015-12-29: Ocular Therapeutix Trading Lower

Financial news for OCUL dated on 2015-12-14: Ocular Therapeutics Reports Encouraging Top-Line Results from Exploratory Phase 2 Trial of DEXTENZA: Showed Benefit in Efficacy Measure, Meaningful Benefit from Supportive Measures

Financial news for OCUL dated on 2015-12-11: 16 Stocks Moving In Friday's After-Hours Session

Financial news for OCUL dated on 2015-12-09: Ocular Therapeutix Reports FDA Acceptance of NDA Filing for DEXTENZA for the Treatment of Post-Surgical Ocular Pain

Financial news for OCUL dated on 2015-12-04: 10 Stocks To Watch In Friday's After-Hours Session

Financial news for OCUL dated on 2015-11-24: Ocular Therapeutix Begins Enrollment in its Second Phase 3 Clinical Trial for DEXTENZA for the Treatment of Allergic Conjunctivitis

Financial news for OCUL dated on 2015-11-11: Morning Market Losers

Financial news for OCUL dated on 2015-11-10: Ocular Therapeutix Reports Q3 EPS \$(0.47) vs. Est. \$(0.38), Rev. \$429K vs. Est. \$500K

Financial news for OCUL dated on 2015-11-02: Ocular Therapeutics Shares Sell Off

Below \$9, Currently \$9.05

Financial news for OCUL dated on 2015-10-22: Ocular Therapeutix Reports Results from Phase 2b Glaucoma Trial Showed Clinically Meaningful Intraocular Pressure Reduction, Improvement in Depot Retention Showed with OTX-TP at Day 75

Financial news for OCUL dated on 2015-10-22: Ocular Therapeutix Reports Results of Phase 3 Trial for DEXTENZA in Allergic Conjunctivitis, Says Met Primary Endpoint

Financial news for OCUL dated on 2015-10-14: Ocular Therapeutix Starts Enrollment in Third Phase 3 Clinical Trial for DEXTENZA for the Treatment of Post-Surgical Ocular Inflammation and Pain

Financial news for OCUL dated on 2015-09-28: Ocular Therapeutix Offers Submission of NDA to FDA for DEXTENZA for Treatment of Post-Surgical Ocular Pain

Financial news for OCUL dated on 2015-09-14: Ocular Therapeutix Adds Jeffrey S. Heier, M.D. To Board

Financial news for OCUL dated on 2015-08-13: Morgan Stanley Initiates Coverage on Ocular Therapeutix at Equal-weight, Announces \$24.00 PT

Financial news for OCUL dated on 2015-08-10: Ocular Therapeutix Reports Q2 Loss of \$0.45/Share vs Loss of \$0.33/Share Est., Sales \$459K vs \$400K Est.

Financial news for OCUL dated on 2015-08-05: Benzinga's Top Initiations

Financial news for OCUL dated on 2015-08-05: Nomura Initiates Coverage on Ocular Therapeutix at Buy, Announces \$46.00 PT

Financial news for OCUL dated on 2015-07-10: 13G Filing from Capital Research Global Partners on Ocular Therapeutix Shows New 11.5% Stake

Financial news for OCUL dated on 2015-06-16: Ocular Therapeutix Reports Commencement of Enrollment for Phase 3 Trial of DEXTENZA for Treatment of Allergic Conjunctivitis

Financial news for OCUL dated on 2015-06-05: US Stock Futures Slip; All Eyes On Jobs Report

Financial news for OCUL dated on 2015-06-05: Ocular Therapeutix Prices 4M Share Offering @\$22.00/Share

Financial news for OCUL dated on 2015-06-02: Ocular Therapeutix, Inc. Announces Proposed Public Offering of Common Stock

Financial news for OCUL dated on 2015-05-20: S-1 Filing From Ocular Therapeutix To Offer \$120M Stock

Financial news for OCUL dated on 2015-05-15: US Stock Futures Edge Higher Ahead Of Economic Data

Financial news for OCUL dated on 2015-05-15: Ocular Therapeutixs Plans to Proceed with an NDA Submission for OTX-DP for Treatment of Post-Surgical Ocular Pain Indication

Financial news for OCUL dated on 2015-05-15: Ocular Therapeutics Q1 EPS -\$0.35 vs -\$0.39 est

Financial news for OCUL dated on 2015-05-15: Earning, Economic & IPO Calendar for Friday May 15, 2015

Financial news for OCUL dated on 2015-05-15: Earnings Scheduled For May 15, 2015

Financial news for OCUL dated on 2015-04-07: Biotech: Anatomy Of An Investing Mania?

Financial news for OCUL dated on 2015-04-07: Morning Market Losers

Financial news for OCUL dated on 2015-04-06: Ocular Therapeutix Shares Plunge Upon Resumption, Now Down ~22%

Financial news for OCUL dated on 2015-04-06: Ocular To Resume Quoting Any Moment, Trading To Resume At 17:00 EDT

Financial news for OCUL dated on 2015-04-06: UPDATE: Ocular Therapeutix Offers Topline Clinical Data for Second Phase 3 Trial of OTX-DP

Financial news for OCUL dated on 2015-04-06: Ocular Therapeutix Offers Topline Clinical Data for Second Phase 3 Trial of OTX-DP: Primary Efficacy Endpoint for Pain Met, for Inflammatory Cells Not Attained

Financial news for OCUL dated on 2015-04-06: Ocular Therapeutix Shares Halted News Pending

Financial news for OCUL dated on 2015-03-10: Adam F Cautious on Ocular Therapeutix

Financial news for OCUL dated on 2015-03-10: US Stock Futures Tumble Ahead Of Wholesale Inventories Data

Financial news for OCUL dated on 2015-03-10: Ocular Therapeutix Q4 EPS -\$0.37 vs -\$0.38 est

Financial news for OCUL dated on 2015-03-10: Ocular Therapeutix Reports Positive Topline Clinical Data for First of Two Phase 3 Clinical Trials Evaluating OTX-DP for Treatment of Post-Surgical Ocular Inflammation and Pain

Financial news for OCUL dated on 2015-03-10: Earnings Scheduled For March 10, 2015

Financial news for OCUL dated on 2015-02-04: IPO Outlook: Inotek's Vision For The Future

Financial news for OCUL dated on 2015-02-02: Stocks Hitting 52-Week Highs

Financial news for OCUL dated on 2015-01-21: Ocular Therapeutix Enrolls First Patient in Phase 2 Clinical Trial for Sustained Release Dexamethasone

Financial news for OCUL dated on 2014-12-16: Stocks Hitting 52-Week Highs

Financial news for OCUL dated on 2014-11-12: US Stock Futures Slide Ahead Of Macy's Earnings

Financial news for OCUL dated on 2014-11-12: Ocular Therapeutix Enrolls First Patients in Phase 2b Clinical Trial for Sustained Release Travoprost for the Treatment of Glaucoma and Ocular Hypertension

Financial news for OCUL dated on 2014-11-12: Ocular Therapeutix Announces Top-Line Results from Phase 2 Sustained Release Dexamethasone Trial for Allergic Conjunctivitis

Financial news for OCUL dated on 2014-11-05: Ocular Therapeutix(tm) to Report Third Quarter 2014 Financial Results and Provide Business Updates on Wednesday, November 12, 2014

Financial news for OCUL dated on 2014-10-08: Ocular Therapeutix Completes Enrollment In Phase 3 Sustained Release Dexamethasone Trials For Post-Operative Inflammation And Pain

Financial news for OCUL dated on 2014-08-19: Benzinga's Top Initiations

Financial news for OCUL dated on 2014-08-19: Oppenheimer Initiates Ocular Therapeutix With Outperform

Financial news for OCUL dated on 2014-08-19: RBC Capital Initiates Coverage on Ocular Therapeutix at Outperform, Announces \$21.00 PT

Financial news for OCUL dated on 2014-08-19: Oppenheimer Initiates Coverage on Ocular Therapeutix at Outperform, Announces \$25.00 PT

Financial news for OCUL dated on 2014-07-25: Ocular Therapeutix Shares Open at \$13, Priced IPO at \$13/Share

Financial news for OCUL dated on 2014-07-25: Waiting on 5 IPOs This Morning

Financial news for OCUL dated on 2014-07-21: IPO Lookout: Lots of Action This Week, But Is Anything A Worthwhile Investment?

Financial news for OCUL dated on 2014-07-11: Ocular Therapeutics Expects 5M Share IPO to Price \$14-\$16/Share

Financial news for OCUL dated on 2014-06-20: Ocular Therapeutix Files up to \$86.25M IPO